U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06975319) titled 'Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers' on April 24.
Brief Summary: Virometix AG, is conducting research into a vaccine (V-212) to prevent pneumococcal disease, which is any type of illness caused by infection with a bacterium called Streptococcus pneumoniae (S. pneumoniae).
This trial is being conducted to obtain insight into the body's immune response and possible adverse effects of the trial vaccine in healthy adult volunteers. Three different doses will be evaluated to identify an optimal dose for future trials.
The trial is a prospective (collects data into the future), randomised, double-blind, phas...